Ipamorelin vs MK-677

Dose, schedule, route and approval status side by side.

Reference only, not medical advice. Doses marked FDA-approved come from the US prescribing label. Doses marked Not approved are ranges reported from small studies or community use and have not been established as safe or effective in humans. Check anything here with a licensed clinician before acting on it. Read the full disclaimer.

	Ipamorelin	MK-677
Status	Not approved	Clinical trials
Also known as	–	ibutamoren
Typical dose	100–300 mcg	10–25 mg
How often	Daily, 1–3 times	Daily
Schedule	One to three times daily, commonly before bed.	Once daily by mouth.
Daily equivalent	100–900 mcg/day	10–25 mg/day
Route	Subcutaneous	Oral
Duration	8–12 weeks reported	Trials ran up to 2 years
Notes	Growth hormone secretagogue. Reached Phase 2 for post-surgical bowel recovery but was not approved.	Not a peptide: an oral ghrelin-receptor agonist. Raises blood sugar and can cause fluid retention. One trial in hip-fracture patients was stopped over heart failure signals.

This page sets the two chart entries next to each other. It does not say which is better or whether either is right for you. Read member experiences on the Ipamorelin and MK-677 pages.

Advertise here